Spectrum begins Phase II of poziotinib to treat NSCLC

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) began a Phase II trial to evaluate once-daily oral poziotinib (HM781-36B, NOV12010) in up to 174 non-small

Read the full 215 word article

User Sign In